Physician profile
John Eric Roddenberry
NPI 1992791628
$2,576.20
in general payments reported to CMS, 2019-2025
30 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $229 · 2021: $392 · 2022: $399 · 2023: $445 · 2024: $391 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.64 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $278.45 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $200.18 | 2019-2024 | Aptima |
| Caldera Medical, INC | $165.49 | 2023 | Desara |
| Mayne Pharma Commercial LLC | $158.49 | 2021-2024 | |
| Baxter Healthcare | $156.22 | 2024-2025 | Starling System, Floseal |
| Amgen INC. | $151.75 | 2019-2020 | |
| Pfizer INC. | $149.13 | 2020-2024 | |
| Edwards Lifesciences Corporation | $117.45 | 2019 | |
| Daiichi Sankyo INC. | $111.29 | 2020-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $80.71 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $69.46 | 2019-2020 | |
| Exeltis, USA INC. | $63.21 | 2021-2023 | Slynd |
| Roche Diagnostics Corporation | $41.98 | 2019 | |
| Boston Scientific Corporation | $39.85 | 2022-2023 | Upsylon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $34.54 | 2025 | Arista |
| Bayer Healthcare Pharmaceuticals INC. | $33.44 | 2019-2022 | |
| Organon LLC | $31.18 | 2022-2023 | Nexplanon |
| Medline Industries LP | $30.65 | 2019 | |
| Meditrina | $28.59 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.08 | 2019 | |
| Allergan, INC. | $18.88 | 2020 | |
| Scynexis, INC. | $15.35 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.94 | 2021 | |
| Minerva Surgical, INC | $14.68 | 2020 | |
| Aspira Women'S Health INC | $14.18 | 2022 | |
| Myovant Sciences INC. | $13.95 | 2021 | |
| Cepheid | $13.93 | 2019 | |
| Therapeuticsmd, INC. | $13.53 | 2019 | |
| Agile Therapeutics, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roddenberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.